| Website | accerapharma.com |
| Category | BioTech |
| Phone | 303.999.3700 |
| Employees | |
| Founded | 2001 |
| Description | Healthcare Biotechnology |
| TOTAL | $61.6M |
| FUNDING TOTAL | $61.6M |
| Series A, 6/04 POSCO BioVentures | $3.05M |
| Series B, 10/06 | $7.5M |
| Venture Round, 8/08 | $5M |
| Series C, 11/08 POSCO BioVentures Inventages Venture Capital Investment Inc. | $35M |
| Series D, 1/11 | $11M |
Accera, Inc., a biotechnology company, engages in the discovery and development of therapeutic drugs for neurodegenerative diseases. It offers Ketasyn, a molecule for Alzheimer’s, Parkinson’s, and age associated memory impairment.
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s. Dispensed by prescription, it targets the metabolic deficiencies and imbalances associated with AD by providing an alternative energy source for brain cells.
